When pharmaceutical process data become manufacturing evidence: Evidence maturity and decision suitability

Modern pharmaceutical manufacturing can generate large volumes of high-frequency process data, but data volume and record integrity alone do not determine what those data can justify. In this Perspective, manufacturing evidence is used as a functional, not legal or regulatory, term for process-related information used to justify a specified manufacturing or lifecycle decision. Established quality, risk, validation, process analytical technology (PAT), and data-integrity frameworks address how manufacturing information is generated, controlled, interpreted, and trusted. The narrower issue considered here is whether a particular body of information is adequate for a particular decision, and where that justification ends. Three maturity levels - descriptive process data, process-understanding evidence, and decision-suitable manufacturing evidence - are considered across six evidentiary dimensions. A published commercial continuous-manufacturing PAT case is re-analyzed using those dimensions, with explicit attention to what the publication does and does not support. The example shows why data adequate for monitoring and control within a demonstrated domain do not automatically justify transfer, release, or other decisions outside that domain. This distinction becomes more consequential as manufacturing increasingly relies on continuous data streams, digital twins, and artificial intelligence.